<DOC>
	<DOCNO>NCT01033552</DOCNO>
	<brief_summary>This open-label , single institution , phase II study patient epidermolysis bullosa ( EB ) . The underlying hypothesis infusion bone marrow umbilical cord blood healthy unaffected donor correct collagen , laminin , integrin , plakin deficiency reduce skin fragility characteristic severe form EB . A secondary hypothesis mesenchymal stem cell healthy donor enhance safety efficacy allogeneic hematopoietic stem cell transplant well serve source renewable cell treatment focal area residual blistering .</brief_summary>
	<brief_title>Stem Cell Transplant Epidermolysis Bullosa</brief_title>
	<detailed_description>The primary objective study estimate event-free survival rate 1 year post-transplant event define death failure demonstrable increase collagen , laminin , integrin , keratin plakin deposition 1 year post-transplant biochemical , structual physical measure improvement . The secondary objective study ) determine incidence transplant-related mortality ( TRM ) 180 day ; ii ) describe pattern biochemical improvement measure increase protein expression ( collagen , laminin , integrin , keratin plakin ) relate structural physical change ; iii ) describe health quality life day 365 730 compare pretreatment result ; iv ) describe pattern durability HSC third party MSC engraftment skin ; v ) determine probability survival 1 year . Patients severe epidermolysis bullosa screen meet eligibility requirement , relate unrelated donor marrow UCB infuse , subject follow minimum 5 year stem cell transplant . A target accrual 75 subject 5 year recruit study .</detailed_description>
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Diagnosis severe form epidermolysis bullosa ( EB ) characterize collagen , laminin , integrin , keratin plakin deficiency . Assessment criterion severe EB : Severe blister disease require dressing &gt; 50 % body surface area Documented collagen , laminin , integrin , keratin plakin deficiency ( immunofluorescence stain protein specific antibody Western blot mutation analysis ) Poor performance status result EB ( Lansky Karnofsky &lt; 50 % ) Adequate Organ Function Criteria Renal : glomerular filtration rate &gt; 60ml/min/1.73m2 patient age ≤ 10 year Hepatic : bilirubin , aspartate aminotransferase/alanine aminotransferase ( AST/ALT ) , Alkaline phosphatase ( ALP ) &lt; 5 x upper limit normal Pulmonary : oxygen saturation &gt; 92 % Cardiac : leave ventricular ejection fraction ≥ 45 % , normal electrocardiogram ( EKG ) approve Cardiology transplant . Performance status : ≥ 50 % Lansky ; ≥ 50 % Karnofsky Available Healthy HSC Donor ( order preference ) Related Donor ( marrow UCB ) HLAA , B , C , DRB1 genotypic identical ( sibling ) donor HLAA , B , C , DRB1 phenotypic identical donor 7/8 HLA match donor HLAA , B , C , DRB1 Unrelated Donor Marrow HLAA , B , C , DRB1 phenotypic identical donor 7/8 HLA match donor HLAA , B , C , DRB1 UCB HLAA , B ( antigen level ) DRB1 ( allele level ) match donor 5/6 HLA match donor HLAA , B , DRB1 4/6 HLA match donor HLAA , B , DRB1 Voluntary write consent Active systemic infection time transplantation ( include active infection Aspergillus mold within 30 day ) . History human immunodeficiency virus ( HIV ) infection Prior transplantation donor skin Evidence squamous cell carcinoma Donor EB Pregnancy breast feeding . Females childbearing age must document negative pregnancy test agree use contraception condition enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>